Biotech pharma

10x Science

Website

10x Science develops frontier AI models with deep memory to redefine how scientists understand and engineer biology across the life sciences, starting with drug development. AI-powered drug discovery is flooding the pipeline with new candidates faster than ever. But before any of them can advance to the clinic, scientists must deeply characteriz

Founded 2025Origin source ↗Checked 2026-09-15

Overview

10x Science develops frontier AI models with deep memory to redefine how scientists understand and engineer biology across the life sciences, starting with drug development.

AI-powered drug discovery is flooding the pipeline with new candidates faster than ever. But before any of them can advance to the clinic, scientists must deeply characterize the protein therapeutic to understand whether it will work. Today, that process takes months of manual, error-prone analysis that cannot keep pace with discovery. Our AI-native platform automates it, giving drug developers the confidence to advance the right candidates and stop the wrong ones early.

We have strong commercial traction with enterprise pharma customers. Our founding team built the field of next-generation protein characterization out of Carolyn Bertozzi's Nobel laureate lab at Stanford. Collectively, we have 18+ years of collective domain expertise, 47+ scientific publications, and a 2x YC Founder. We move at the highest velocity and are positioned to lead the next generation of modern AI development in the life sciences.

Company description As recorded 2026-11-08

Founders & team

David Roberts

Founder/CEO

Chemistry postdoc and Damon Runyon Cancer Research Fellow in Prof. Carolyn Bertozzi's lab (2022 Nobel Prize in Chemistry) at Stanford University. Next-generation scientific leader in chemical biology and glycobiology with 1600+ citations & h-index 23. Received my B.S. double major in chemistry & mathematics at UC San Diego (2016) and Ph.D. in materials chemistry & analytical chemistry at the University of Wisconsin-Madison (2023).

Founder profile As recorded 2026-09-15

Andrew Reiter

Founder/COO

Previously received my B.S. in Biology from UNC-Chapel Hill. I then joined Dr. Steven Carr’s Proteomics Platform Lab at the Broad Institute of MIT and Harvard, where I developed new methods in mass spectrometry. I later became a Ph.D. student and NSF-GRFP fellow in the Department of Biology at Stanford University, where I was co-advised by Dr. Carolyn Bertozzi (2022 Nobel Laureate in Chemistry) and Dr. Or Gozani.

Founder profile As recorded 2026-09-15

Vishnu Tejus

Founder/CTO

I am a 2x YC Founder. Previously, I built AI for go-to-market teams as the 2nd hire and founding engineer at Nooks. Then, I forward deployed myself in research labs at the University of Washington, UCSF, and Stanford, where I was mentored by world-renowned scientists in analytical chemistry and cancer research. In < 1 year, I published 2 papers and won 4 national awards. Now, I'm building ultrafast AI models for drug discovery teams to characterize proteins and pharmaceutical candidates.

Founder profile As recorded 2026-09-15
5team members reported
Source-reported As recorded 2026-09-15

Founded 2025 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationsite error
Last website check2026-11-11
Location · source statedSan Francisco, CA, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The latest website check does not confirm this company’s website.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationdescriptive evidenceclassified market and modelsourced peoplesourced founding year